As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.
Last month, during a forum organized by US News & World Report, Amy Caro, vice president of health IT programs at Northrop
Northrop Grumman received the award under the BioWatch Gen-3 System Performance Demonstration Contract, and said that the contract could be worth up to $37 million over three years.
Agilent Technologies, Columbia University, and others are collaborating on development of the system, which will be based on MassTag PCR.
The firms won grants to develop integrated diagnostic systems used to counter natural or man-made biological threats.
The companies will use Luminex's xMAP technology to develop an automated biothreat detection tool for a US biosecurity network.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.